Lutetium 177 clinical trials. There are currently ongoing clinical trials as...
Lutetium 177 clinical trials. There are currently ongoing clinical trials assessing the activity of 177 Lu-DOTA-TATE and 177 Lu-PSMA-617 on SSTR and PSMA-expressing tumors as listed in Table I. Nov 18, 2024 · “This is a significant accomplishment for Curium, demonstrating in the pivotal confirmatory ECLIPSE trial a statistically significant and clinically meaningful benefit of PSMA-targeted radioligand therapy with 177 Lu-PSMA-I&T for patients with mCRPC. In this study, we describe the blood pharmacokinetics behavior, biodistribution, and dosimetry of 177 Lu-PSMA-617 to support its clinical use in Chinese participants. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations. Explore clinical trials for advanced prostate cancer treatments and diagnostics, including Lu-177-PSMA and Copper Cu64 PSMA. Apr 24, 2025 · The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \ [177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. Herein we present new clinical results with a focus on pts with mCRPC who received Lu 177 treatment. DB-1311/BNT324 is an investigational B7H3 ADC with encouraging activity in pts with heavily pretreated mCRPC (ASCO 2025 #5015). 2 days ago · The pharmacokinetics, dosimetry, and safety of 177 Lu-PSMA-617 in participants with metastatic castration-resistant prostate cancer are described previously. All News Consumer Pro New Drugs Pipeline Clinical Trials FDA Alerts Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to Lutathera BEDFORD, Mass. Clinical trial information: NCT05547061. Jul 31, 2025 · This is a prospective, open-label, multi-center, randomized, Phase 3 study evaluating Lutetium 177Lu-PSMA-I&T as treatment compared to standard of care hormone therapy in men with metastatic Castration-Resistant Prostate Cancer. 5 days ago · The Phase 3 ECLIPSE clinical trial evaluates lutetium-177 (Lu-177) zadavotide guraxetan (a proprietary formulation of 177 Lu-PSMA-I&T), an investigational prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior 1 day ago · The ECLIPSE sub-study evaluated PK and radiation dosimetry of Lutetium Lu 177 zadavotide guraxetan in a subset of patients. Review the clinical trials studying lutetium lu 177 dotatate on this list and use the filters to refine the results by age and location. 1 day ago · Conclusions: Lu-177-DGUL demonstrated promising anti-tumor activity and a manageable safety profile in PSMA-positive mCRPC. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find 14 hours ago · Research continues to explore combining this therapy with other targeted treatments, immunotherapies, or hormone therapies to maximize outcomes. 1 day ago · The FDA has tentatively approved the abbreviated new drug application for the lutetium lu 177 dotatate radioequivalent PNT2003 in SSTR-positive GEP-NETs. Jan 20, 2024 · Metastatic castration-resistant prostate cancer presents treatment challenges, including the side effects of chemotherapy. 1 day ago · Preclinical studies demonstrated superior anti-tumor activity of Tb-161 PSMA compared with the Lu-177 PSMA. 1 day ago · Moreover, data on clinical outcomes following Lu 177 is limited. Methods: Biodistribution, PK and radiation dosimetry were assessed in a subset of 26 patients (not randomized to the main ECLIPSE trial). 5 days ago · The Phase 3 ECLIPSE clinical trial evaluates lutetium-177 (Lu-177) zadavotide guraxetan (a proprietary formulation of 177 Lu-PSMA-I&T), an investigational prostate-specific membrane antigen (PSMA 1 day ago · Conclusions: In this real-world analysis of patients who received 177 Lu-PSMA-617 after sipuleucel-T treatment, the median PFS was similar to that observed in clinical trials, suggesting that 177 Lu-PSMA-617 can be sequenced after sipuleucel-T treatment in appropriate patients. Recent clinical trials indicate that Lutetium-177 therapy not only slows disease progression but may also enhance survival rates for patients with metastatic prostate cancer. , March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Clinical Implications: Where Does Pluvicto Fit in mHSPC? The PSMA Addition trial provides proof-of-concept that PSMA-targeted radioligand therapy can improve outcomes in mHSPC. Mayo Clinic researchers find that lutetium-177 prolongs radiographic progression-free survival in patients yet to receive taxane chemotherapy. 2 days ago · While difficult to implement in phase III trials, this approach may become increasingly relevant in clinical practice as experience grows. The consistent anti-tumor activity observed across subgroups, including pre- and post-taxane, highlights its potential as a robust treatment for mCRPC. 4 days ago · The Phase 3 ECLIPSE clinical trial evaluates lutetium-177 (Lu-177) zadavotide guraxetan (a proprietary formulation of 177 Lu-PSMA-I&T), an investigational prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior . Furthermore, safety of Tb-161 I&T has been documented recently with VIOLET trial as the first in human study. tsr onr eea xmf dqt rsk wfo lwz zcz aus uai pez sxh gss nka
